^
    Back
    Association details:
    Biomarker:miR-155 expression
    Cancer:HER2 Positive Breast Cancer
    Drug:letrozole (Aromatase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Exp Oncol
    Title:

    ASSOCIATION OF miRNA EXPRESSION PATTERN WITH OUTCOME OF LETROZOLE THERAPY IN BREAST CANCER PATIENTS

    Published date:
    10/11/2023
    Excerpt:
    Most HER2/neu+ BC patients had low levels of miR-155 and miR-221 expression in tumor biopsy specimens. Tumors that responded well to letrozole exhibited lower levels of miR-125b-2 and miR-221 compared to non-responsive tumors….miR-125b-2, -155, and -221 expression can predict resistance to the letrozole treatment of BC.
    DOI:
    https://doi.org/10.15407/exp-oncology.2023.02.180